[Treatment of anemia with erythropoietin (rhuEPO) in patients with chronic kidney failure who are not yet in need of dialysis therapy].
Eleven uraemic predialysis patients have been selected for the treatment of anaemia with rhuEPO. Administration of rhuEPO was followed by a significant increase of the Hct value and haemoglobin concentration as well as an improvement of well being. The main adverse effects of rhuEPO therapy were the following: increase of blood pressure, reduction of the residual renal function and increase of serum potassium and phosphorous concentration. Monitoring of the iron status in uraemic predialysis patients on rhuEPO therapy seems to be mandatory.
Wiecek
A
A
Katedry i Kliniki Nefrologii Sl. AM, Katowicach.
Kokot
F
F
Marcinkowski
W
W
Rudka
R
R
Klimek
D
D
D000328:Adult; D000368:Aged; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D004921:Erythropoietin
Leczenie niedokrwistości erytropoetyna (rhuEPO) u chorych z przewlekła niewydolnościa nerek nie wymagajacych jeszcze dializoterapii.